142 results on '"Pierantozzi, M."'
Search Results
2. Modeling the viscosity of ionic liquids using combined friction theory with perturbed hard-chain equation of state and neural network approaches
- Author
-
Moslehi, H., Hosseini, S.M., Pierantozzi, M., Alavianmehr, M.M., and Haghighi, B.
- Published
- 2023
- Full Text
- View/download PDF
3. Molecular thermodynamic modeling of surface tension: Extension to molten polymers
- Author
-
Hoseini, S., Yousefi, F., Hosseini, S.M., and Pierantozzi, M.
- Published
- 2022
- Full Text
- View/download PDF
4. The Retinal Posterior Pole in Early Parkinson’s Disease: A Fundus Perimetry and SD-OCT Study
- Author
-
Cesareo M, Di Marco E, Giannini C, Di Marino M, Aiello F, Pisani A, Pierantozzi M, Mercuri NB, Nucci C, and Mancino R
- Subjects
parkinson's disease ,optical coherence tomography ,retina ,dopamine ,alpha-synuclein ,Ophthalmology ,RE1-994 - Abstract
Massimo Cesareo,1 Ernesto Di Marco,1 Clarissa Giannini,1 Matteo Di Marino,1 Francesco Aiello,1 Antonio Pisani,2 Mariangela Pierantozzi,3 Nicola Biagio Mercuri,4,5 Carlo Nucci,1 Raffaele Mancino1 1Ophthalmology Unit, Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy; 2Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; 3Parkinson’s Center, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; 4Neurology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; 5Fondazione Santa Lucia I.R.C.C.S, Rome, ItalyCorrespondence: Massimo Cesareo; Ernesto Di MarcoOphthalmology Unit, Department of Experimental Medicine University of Rome “Tor Vergata”, via Montpellier, Rome, 100133, ItalyTel/Fax +39 0620902973Email massimo.cesareo@uniroma2.it; Ernesto2601@hotmail.itPurpose: To assess the structure and function of the retinal posterior pole in patients with early Parkinson’s disease (PD) and to identify possible biomarkers correlated with clinical features.Patients and Methods: A cross-sectional case-control study of 21 patients with PD and 22 age-matched healthy controls (HC) was conducted. All subjects underwent full ophthalmological examinations, fundus perimetry (FP) and spectral domain-OCT (SD-OCT) of the entire retinal posterior pole and peripapillary retinal nerve fiber layer (pRNFL).Results: We analyzed 41 eyes from 21 patients (14 males and 7 females) with early PD (Hoehn and Yahr scale (H&Y) equal to or less than stage 2) and 41 eyes from 22 HC (12 males and 10 females). We found no significant difference in the pRNFL thickness between patients with PD and HC. The statistical analysis of the SD-OCT posterior pole area, consisting of 64 values for each retinal layer, revealed a decrease in the outer nuclear layer (ONL) thickness in patients with PD (p < 0.0001). On the contrary, a significant increase in the thickness of the outer plexiform layer (OPL) (p < 0.0001) and of the retinal pigmented epithelium (RPE) (p= 0.002) compared to healthy controls was detected. Other retinal layers showed no significant statistical differences. The differential light sensitivity (DLS) values measured by FP were significantly lower in patients than the healthy controls (15 [13– 16.2] vs 17.95 [16.08– 18.96] p< 0.0001).Conclusion: Our results showed that DLS and retinal structure differed in the posterior pole between patients with early PD and controls. Thickening of the OPL may represent accumulation of α-synuclein in the OPL of patients with PD.Keywords: Parkinson’s disease, optical coherence tomography, retina, dopamine, alpha-synuclein
- Published
- 2021
5. Correction to: Viscosities of Liquid Refrigerants from a Rough Hard-Sphere Theory-Based Semi-Empirical Model
- Author
-
Yousefi, F., Hosseini, S. M., Hamidi, K., and Pierantozzi, M.
- Published
- 2022
- Full Text
- View/download PDF
6. Predicting the volumetric properties of pure and mixture of amino acid-based ionic liquids
- Author
-
Taghizadehfard, M., Hosseini, S.M., Pierantozzi, M., and Alavianmehr, M.M.
- Published
- 2019
- Full Text
- View/download PDF
7. An Artificial Neural Network for the surface tension of alcohols
- Author
-
Mulero, Ángel, Pierantozzi, M., Cachadiña, Isidro, and Di Nicola, G.
- Published
- 2017
- Full Text
- View/download PDF
8. Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease: An individual patient data meta-analysis
- Author
-
Singh, B, Lant, S, Cividini, S, Cattrall, J, Goodwin, L, Benjamin, L, Michael, B, Khawaja, A, Matos, A, Alkeridy, W, Pilotto, A, Lahiri, D, Rawlinson, R, Mhlanga, S, Lopez, E, Sargent, B, Somasundaran, A, Tamborska, A, Webb, G, Younas, K, Al Sami, Y, Babu, H, Banks, T, Cavallieri, F, Cohen, M, Davies, E, Dhar, S, Modol, A, Farooq, H, Harte, J, Hey, S, Joseph, A, Karthikappallil, D, Kassahun, D, Lipunga, G, Mason, R, Minton, T, Mond, G, Poxon, J, Rabas, S, Soothill, G, Zedde, M, Yenkoyan, K, Brew, B, Contini, E, Cysique, L, Zhang, X, Maggi, P, van Pesch, V, Lechien, J, Saussez, S, Heyse, A, Brito Ferreira, M, Soares, C, Elicer, I, Eugenin-Von Bernhardi, L, Reyes, W, Yin, R, Azab, M, Abd-Allah, F, Elkady, A, Escalard, S, Corvol, J, Delorme, C, Tattevin, P, Bigaut, K, Lorenz, N, Hornuss, D, Hosp, J, Rieg, S, Wagner, D, Knier, B, Lingor, P, Winkler, A, Sharifi-Razavi, A, Moein, S, Seyed Alinaghi, S, Jamali Moghadam Siahkali, S, Morassi, M, Padovani, A, Giunta, M, Libri, I, Beretta, S, Ravaglia, S, Foschi, M, Calabresi, P, Primiano, G, Servidei, S, Mercuri, N, Liguori, C, Pierantozzi, M, Sarmati, L, Boso, F, Garazzino, S, Mariotto, S, Patrick, K, Costache, O, Pincherle, A, Klok, F, Meza, R, Cabreira, V, Valdoleiros, S, Oliveira, V, Kaimovsky, I, Guekht, A, Koh, J, Diaz, E, Barrios-Lopez, J, Guijarro-Castro, C, Beltran-Corbellini, A, Martinez-Poles, J, Diezma-Martin, A, Morales-Casado, M, Garcia, S, Breville, G, Coen, M, Uginet, M, Bernard-Valnet, R, Pasquier, R, Kaya, Y, Abdelnour, L, Rice, C, Morrison, H, Defres, S, Huda, S, Enright, N, Hassell, J, D'Anna, L, Benger, M, Sztriha, L, Raith, E, Chinthapalli, K, Nortley, R, Paterson, R, Chandratheva, A, Werring, D, Dervisevic, S, Harkness, K, Pinto, A, Jillella, D, Beach, S, Gunasekaran, K, Ferreira Da Silva, I, Nalleballe, K, Santoro, J, Scullen, T, Kahn, L, Kim, C, Thakur, K, Jain, R, Umapathi, T, Nicholson, T, Sejvar, J, Hodel, E, Smith, C, Solomon, T, Singh B., Lant S., Cividini S., Cattrall J. W. S., Goodwin L. C., Benjamin L., Michael B. D., Khawaja A., Matos A. D. M. B., Alkeridy W., Pilotto A., Lahiri D., Rawlinson R., Mhlanga S., Lopez E. C., Sargent B. F., Somasundaran A., Tamborska A., Webb G., Younas K., Al Sami Y., Babu H., Banks T., Cavallieri F., Cohen M., Davies E., Dhar S., Modol A. F., Farooq H., Harte J., Hey S., Joseph A., Karthikappallil D., Kassahun D., Lipunga G., Mason R., Minton T., Mond G., Poxon J., Rabas S., Soothill G., Zedde M., Yenkoyan K., Brew B., Contini E., Cysique L., Zhang X., Maggi P., van Pesch V., Lechien J., Saussez S., Heyse A., Brito Ferreira M. L., Soares C. N., Elicer I., Eugenin-Von Bernhardi L., Reyes W. N., Yin R., Azab M. A., Abd-Allah F., Elkady A., Escalard S., Corvol J. -C., Delorme C., Tattevin P., Bigaut K., Lorenz N., Hornuss D., Hosp J., Rieg S., Wagner D., Knier B., Lingor P., Winkler A. S., Sharifi-Razavi A., Moein S. T., Seyed Alinaghi S. A., Jamali Moghadam Siahkali S., Morassi M., Padovani A., Giunta M., Libri I., Beretta S., Ravaglia S., Foschi M., Calabresi P., Primiano G., Servidei S., Mercuri N. B., Liguori C., Pierantozzi M., Sarmati L., Boso F., Garazzino S., Mariotto S., Patrick K. N., Costache O., Pincherle A., Klok F. A., Meza R., Cabreira V., Valdoleiros S. R., Oliveira V., Kaimovsky I., Guekht A., Koh J., Diaz E. F., Barrios-Lopez J. M., Guijarro-Castro C., Beltran-Corbellini A., Martinez-Poles J., Diezma-Martin A. M., Morales-Casado M. I., Garcia S. G., Breville G., Coen M., Uginet M., Bernard-Valnet R., Pasquier R. D., Kaya Y., Abdelnour L. H., Rice C., Morrison H., Defres S., Huda S., Enright N., Hassell J., D'Anna L., Benger M., Sztriha L., Raith E., Chinthapalli K., Nortley R., Paterson R., Chandratheva A., Werring D. J., Dervisevic S., Harkness K., Pinto A., Jillella D., Beach S., Gunasekaran K., Ferreira Da Silva I. R., Nalleballe K., Santoro J., Scullen T., Kahn L., Kim C. Y., Thakur K. T., Jain R., Umapathi T., Nicholson T. R., Sejvar J. J., Hodel E. M., Smith C. T., Solomon T., Singh, B, Lant, S, Cividini, S, Cattrall, J, Goodwin, L, Benjamin, L, Michael, B, Khawaja, A, Matos, A, Alkeridy, W, Pilotto, A, Lahiri, D, Rawlinson, R, Mhlanga, S, Lopez, E, Sargent, B, Somasundaran, A, Tamborska, A, Webb, G, Younas, K, Al Sami, Y, Babu, H, Banks, T, Cavallieri, F, Cohen, M, Davies, E, Dhar, S, Modol, A, Farooq, H, Harte, J, Hey, S, Joseph, A, Karthikappallil, D, Kassahun, D, Lipunga, G, Mason, R, Minton, T, Mond, G, Poxon, J, Rabas, S, Soothill, G, Zedde, M, Yenkoyan, K, Brew, B, Contini, E, Cysique, L, Zhang, X, Maggi, P, van Pesch, V, Lechien, J, Saussez, S, Heyse, A, Brito Ferreira, M, Soares, C, Elicer, I, Eugenin-Von Bernhardi, L, Reyes, W, Yin, R, Azab, M, Abd-Allah, F, Elkady, A, Escalard, S, Corvol, J, Delorme, C, Tattevin, P, Bigaut, K, Lorenz, N, Hornuss, D, Hosp, J, Rieg, S, Wagner, D, Knier, B, Lingor, P, Winkler, A, Sharifi-Razavi, A, Moein, S, Seyed Alinaghi, S, Jamali Moghadam Siahkali, S, Morassi, M, Padovani, A, Giunta, M, Libri, I, Beretta, S, Ravaglia, S, Foschi, M, Calabresi, P, Primiano, G, Servidei, S, Mercuri, N, Liguori, C, Pierantozzi, M, Sarmati, L, Boso, F, Garazzino, S, Mariotto, S, Patrick, K, Costache, O, Pincherle, A, Klok, F, Meza, R, Cabreira, V, Valdoleiros, S, Oliveira, V, Kaimovsky, I, Guekht, A, Koh, J, Diaz, E, Barrios-Lopez, J, Guijarro-Castro, C, Beltran-Corbellini, A, Martinez-Poles, J, Diezma-Martin, A, Morales-Casado, M, Garcia, S, Breville, G, Coen, M, Uginet, M, Bernard-Valnet, R, Pasquier, R, Kaya, Y, Abdelnour, L, Rice, C, Morrison, H, Defres, S, Huda, S, Enright, N, Hassell, J, D'Anna, L, Benger, M, Sztriha, L, Raith, E, Chinthapalli, K, Nortley, R, Paterson, R, Chandratheva, A, Werring, D, Dervisevic, S, Harkness, K, Pinto, A, Jillella, D, Beach, S, Gunasekaran, K, Ferreira Da Silva, I, Nalleballe, K, Santoro, J, Scullen, T, Kahn, L, Kim, C, Thakur, K, Jain, R, Umapathi, T, Nicholson, T, Sejvar, J, Hodel, E, Smith, C, Solomon, T, Singh B., Lant S., Cividini S., Cattrall J. W. S., Goodwin L. C., Benjamin L., Michael B. D., Khawaja A., Matos A. D. M. B., Alkeridy W., Pilotto A., Lahiri D., Rawlinson R., Mhlanga S., Lopez E. C., Sargent B. F., Somasundaran A., Tamborska A., Webb G., Younas K., Al Sami Y., Babu H., Banks T., Cavallieri F., Cohen M., Davies E., Dhar S., Modol A. F., Farooq H., Harte J., Hey S., Joseph A., Karthikappallil D., Kassahun D., Lipunga G., Mason R., Minton T., Mond G., Poxon J., Rabas S., Soothill G., Zedde M., Yenkoyan K., Brew B., Contini E., Cysique L., Zhang X., Maggi P., van Pesch V., Lechien J., Saussez S., Heyse A., Brito Ferreira M. L., Soares C. N., Elicer I., Eugenin-Von Bernhardi L., Reyes W. N., Yin R., Azab M. A., Abd-Allah F., Elkady A., Escalard S., Corvol J. -C., Delorme C., Tattevin P., Bigaut K., Lorenz N., Hornuss D., Hosp J., Rieg S., Wagner D., Knier B., Lingor P., Winkler A. S., Sharifi-Razavi A., Moein S. T., Seyed Alinaghi S. A., Jamali Moghadam Siahkali S., Morassi M., Padovani A., Giunta M., Libri I., Beretta S., Ravaglia S., Foschi M., Calabresi P., Primiano G., Servidei S., Mercuri N. B., Liguori C., Pierantozzi M., Sarmati L., Boso F., Garazzino S., Mariotto S., Patrick K. N., Costache O., Pincherle A., Klok F. A., Meza R., Cabreira V., Valdoleiros S. R., Oliveira V., Kaimovsky I., Guekht A., Koh J., Diaz E. F., Barrios-Lopez J. M., Guijarro-Castro C., Beltran-Corbellini A., Martinez-Poles J., Diezma-Martin A. M., Morales-Casado M. I., Garcia S. G., Breville G., Coen M., Uginet M., Bernard-Valnet R., Pasquier R. D., Kaya Y., Abdelnour L. H., Rice C., Morrison H., Defres S., Huda S., Enright N., Hassell J., D'Anna L., Benger M., Sztriha L., Raith E., Chinthapalli K., Nortley R., Paterson R., Chandratheva A., Werring D. J., Dervisevic S., Harkness K., Pinto A., Jillella D., Beach S., Gunasekaran K., Ferreira Da Silva I. R., Nalleballe K., Santoro J., Scullen T., Kahn L., Kim C. Y., Thakur K. T., Jain R., Umapathi T., Nicholson T. R., Sejvar J. J., Hodel E. M., Smith C. T., and Solomon T.
- Abstract
Background Neurological COVID-19 disease has been reported widely, but published studies often lack information on neurological outcomes and prognostic risk factors. We aimed to describe the spectrum of neurological disease in hospitalised COVID-19 patients; characterise clinical outcomes; and investigate factors associated with a poor outcome. Methods We conducted an individual patient data (IPD) meta-analysis of hospitalised patients with neurological COVID-19 disease, using standard case definitions. We invited authors of studies from the first pandemic wave, plus clinicians in the Global COVID-Neuro Network with unpublished data, to contribute. We analysed features associated with poor outcome (moderate to severe disability or death, 3 to 6 on the modified Rankin Scale) using multivariable models. Results We included 83 studies (31 unpublished) providing IPD for 1979 patients with COVID-19 and acute new-onset neurological disease. Encephalopathy (978 [49%] patients) and cerebrovascular events (506 [26%]) were the most common diagnoses. Respiratory and systemic symptoms preceded neurological features in 93% of patients; one third developed neurological disease after hospital admission. A poor outcome was more common in patients with cerebrovascular events (76% [95% CI 67–82]), than encephalopathy (54% [42–65]). Intensive care use was high (38% [35–41]) overall, and also greater in the cerebrovascular patients. In the cerebrovascular, but not encephalopathic patients, risk factors for poor outcome included breathlessness on admission and elevated D-dimer. Overall, 30-day mortality was 30% [27–32]. The hazard of death was comparatively lower for patients in the WHO European region. Interpretation Neurological COVID-19 disease poses a considerable burden in terms of disease outcomes and use of hospital resources from prolonged intensive care and inpatient admission; preliminary data suggest these may differ according to WHO regions and country income levels. The dif
- Published
- 2022
9. Viscosities of Liquid Refrigerants from a Rough Hard-Sphere Theory-Based Semi-Empirical Model
- Author
-
Yousefi, F., Hosseini, S. M., Hamidi, K., and Pierantozzi, M.
- Published
- 2019
- Full Text
- View/download PDF
10. Semi-empirical correlations and an artificial neural network for liquid dynamic viscosity of low GWP refrigerants
- Author
-
Di Nicola, G, primary, Tomassetti, S, additional, Pierantozzi, M, additional, and Muciaccia, P F, additional
- Published
- 2022
- Full Text
- View/download PDF
11. Comparison of different diagnostic methods for the detection of Enteromyxum leei (Myxozoa) in farmed gilthead sea bream (Sparus aurata)
- Author
-
Gustinelli, A., Caffara, M., Magri, A., Pierantozzi, M., and Fioravanti, M.
- Abstract
Enteromyxum leei is an enteric Myxozoan parasite causing the so-called “razor blade syndrome” in gilthead sea bream (Sparus aurata), a chronic condition characterized by a progressive weight loss up to emaciation in adult fish. Currently no treatments are found to be effective against this parasite, but a recent experimental study showed promising results using a functional feed for mitigating enteromyxosis (Palenzuela et al., 2020. Dis. Aquat. Org., 138, 111–120). During a field trial aimed to confirm the efficacy of this functional feed in an Italian sea bream facility where enteromyxosis was already known to be present, different methods for the detection of E. leei were compared to establish the more reliable diagnostic test also in relation to a non-lethal approach.
- Published
- 2022
- Full Text
- View/download PDF
12. Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease: An individual patient data meta-analysis
- Author
-
Singh, B., Lant, S., Cividini, S., Cattrall, J.W.S., Goodwin, L.C., Benjamin, L., Michael, B.D., Khawaja, A., Matos, A.D.B., Alkeridy, W., Pilotto, A., Lahiri, D., Rawlinson, R., Mhlanga, S., Lopez, E.C., Sargent, B.F., Somasundaran, A., Tamborska, A., Webb, G., Younas, K., Sami, Y. al, Babu, H., Banks, T., Cavallieri, F., Cohen, M., Davies, E., Dhar, S., Modol, A.F., Farooq, H., Harte, J., Hey, S., Joseph, A., Karthikappallil, D., Kassahun, D., Lipunga, G., Mason, R., Minton, T., Mond, G., Poxon, J., Rabas, S., Soothill, G., Zedde, M., Yenkoyan, K., Brew, B., Contini, E., Cysique, L., Zhang, X., Maggi, P., Pesch, V. van, Lechien, J., Saussez, S., Heyse, A., Ferreira, M.L.B., Soares, C.N., Elicer, I., Eugenin-von Bernhardi, L., Reyes, W.N., Yin, R., Azab, M.A., Abd-Allah, F., Elkady, A., Escalard, S., Corvol, J.C., Delorme, C., Tattevin, P., Bigaut, K., Lorenz, N., Hornuss, D., Hosp, J., Rieg, S., Wagner, D., Knier, B., Lingor, P., Winkler, A.S., Sharifi-Razavi, A., Moein, S.T., SeyedAlinaghi, S., JamaliMoghadamSiahkali, S., Morassi, M., Padovani, A., Giunta, M., Libri, I., Beretta, S., Ravaglia, S., Foschi, M., Calabresi, P., Primiano, G., Servidei, S., Mercuri, N.B., Liguori, C., Pierantozzi, M., Sarmati, L., Boso, F., Garazzino, S., Mariotto, S., Patrick, K.N., Costache, O., Pincherle, A., Klok, F.A., Meza, R., Cabreira, V., Valdoleiros, S.R., Oliveira, V., Kaimovsky, I., Guekht, A., Koh, J., Diaz, E.F., Barrios-Lopez, J.M., Guijarro-Castro, C., Beltran-Corbellini, A., Martinez-Poles, J., Diezma-Martin, A.M., Morales-Casado, M.I., Garcia, S.G., Breville, G., Coen, M., Uginet, M., Bernard-Valnet, R., Pasquier, R. du, Kaya, Y., Abdelnour, L.H., Rice, C., Morrison, H., Defres, S., Huda, S., Enright, N., Hassell, J., D'Anna, L., Benger, M., Sztriha, L., Raith, E., Chinthapalli, K., Nortley, R., Paterson, R., Chandratheva, A., Werring, D.J., Dervisevic, S., Harkness, K., Pinto, A., Jillella, D., Beach, S., Gunasekaran, K., Silva, I.R.F. da, Nalleballe, K., Santoro, J., Scullen, T., Kahn, L., Kim, C.Y., Thakur, K.T., Jain, R., Umapathi, T., Nicholson, T.R., Sejvar, J.J., Hodel, E.M., Smith, C.T., Solomon, T., Brain Infect Global COVID-Neuro Ne, University of Liverpool, Fondation Ophtalmologique Adolphe de Rothschild [Paris], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Pontchaillou [Rennes], ARN régulateurs bactériens et médecine (BRM), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Les Hôpitaux Universitaires de Strasbourg (HUS), The study was funded by the UK Medical Research Council’s Global Effort on COVID-19 Programme (MR/V033441/1) (https://mrc.ukri.org/), UK National Institute for Health Research (NIHR)- funded Global Health Research Group on Acute Brain Infections (17/63/110) (https://www.nihr.ac.uk/), and the NIHR Health Protection Research Unit in Emerging and Zoonotic Infections (NIHR200907), at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford (Grant Nos. IS-HPU-1112-10117 and NIHR200907). These grants were awarded to TS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
- Subjects
General Science & Technology ,[SDV]Life Sciences [q-bio] ,Autonomic dysfunction ,PROVISIONAL CASE DEFINITIONS ,MESH: Hospitalization ,MESH: Prognosis ,MESH: Stroke ,MESH: Risk Factors ,Risk Factors ,MESH: COVID-19 ,Humans ,Multidisciplinary ,Science & Technology ,Hospitalization ,Prognosis ,COVID-19 ,Stroke ,MESH: Humans ,Metaanalysis ,Hospitals ,Brain Infections Global COVID-Neuro Network Study Group ,Multidisciplinary Sciences ,Medical risk factors ,Settore MED/26 - NEUROLOGIA ,Cerebrospinal fluid ,Encephalitis ,Science & Technology - Other Topics ,Dementia - Abstract
Background Neurological COVID-19 disease has been reported widely, but published studies often lack information on neurological outcomes and prognostic risk factors. We aimed to describe the spectrum of neurological disease in hospitalised COVID-19 patients; characterise clinical outcomes; and investigate factors associated with a poor outcome. Methods We conducted an individual patient data (IPD) meta-analysis of hospitalised patients with neurological COVID-19 disease, using standard case definitions. We invited authors of studies from the first pandemic wave, plus clinicians in the Global COVID-Neuro Network with unpublished data, to contribute. We analysed features associated with poor outcome (moderate to severe disability or death, 3 to 6 on the modified Rankin Scale) using multivariable models. Results We included 83 studies (31 unpublished) providing IPD for 1979 patients with COVID-19 and acute new-onset neurological disease. Encephalopathy (978 [49%] patients) and cerebrovascular events (506 [26%]) were the most common diagnoses. Respiratory and systemic symptoms preceded neurological features in 93% of patients; one third developed neurological disease after hospital admission. A poor outcome was more common in patients with cerebrovascular events (76% [95% CI 67–82]), than encephalopathy (54% [42–65]). Intensive care use was high (38% [35–41]) overall, and also greater in the cerebrovascular patients. In the cerebrovascular, but not encephalopathic patients, risk factors for poor outcome included breathlessness on admission and elevated D-dimer. Overall, 30-day mortality was 30% [27–32]. The hazard of death was comparatively lower for patients in the WHO European region. Interpretation Neurological COVID-19 disease poses a considerable burden in terms of disease outcomes and use of hospital resources from prolonged intensive care and inpatient admission; preliminary data suggest these may differ according to WHO regions and country income levels. The different risk factors for encephalopathy and stroke suggest different disease mechanisms which may be amenable to intervention, especially in those who develop neurological symptoms after hospital admission.
- Published
- 2022
13. Nuove modalità di abitare in relazione alla crisi sanitaria
- Author
-
Pierantoni, I., Pierantozzi, M., and Sargolini, M.
- Published
- 2022
14. CSF lactate levels, τ proteins, cognitive decline: a dynamic relationship in Alzheimerʼs disease
- Author
-
Liguori, C, Stefani, A, Sancesario, G, Sancesario, G M, Marciani, M G, and Pierantozzi, M
- Published
- 2015
- Full Text
- View/download PDF
15. Restless legs syndrome and post polio syndrome: a case−control study
- Author
-
Romigi, A., Pierantozzi, M., Placidi, F., Evangelista, E., Albanese, M., Liguori, C., Nazzaro, M., Risina, B. U., Simonelli, V., Izzi, F., Mercuri, N. B., and Desiato, M. T.
- Published
- 2015
- Full Text
- View/download PDF
16. Compliance with levodopa-carbidopa intestinal gel in a selected population in central south Italy: Beyond sex, a possible gender effect
- Author
-
Cerroni, R., Scalise, S., Imbriani, P., Liguori, C., Pierantozzi, M., Pisani, A., Mercuri, N.B., and Stefani, A.
- Published
- 2020
- Full Text
- View/download PDF
17. Idoneità lavorativa, ergonomia e aspetti medico-legali nella Malattia di Parkinson
- Author
-
Gentili, S, Capici, S, Di Lazzaro, G, Ebner, G, Livigni, L, Magrini, A, Marsella, Lt, Mencarelli, R, Mugnaini, S, Olivieri, E, Pierantozzi, M, Pietroiusti, A, Pisani, A, and Stefani, A
- Subjects
Settore MED/44 - Medicina del Lavoro - Published
- 2018
18. Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up
- Author
-
Sensi, M., Cossu, G., Mancini, F., Pilleri, M., Zibetti, M., Modugno, N., Quatrale, R., Tamma, F., Antonini, A., Aguggia, M., Amboni, M., Arca, R., Bartolomei, L., Bonetto, N., Calandra-Buonaura, G., Bove, F., Calandrella, D., Canesi, M., Cannas, A., Capecci, M., Caputo, E., Ceravolo, M. G., Ceravolo, R., Cerrone, G., Coletti Moja, M., Comi, C., Cortelli, P., D'Antonio, P., Dematteis, F., Di Lazzaro, V., Eleopra, R., Fabbrini, G., Fichera, M., Grassi, E., Guido, M., Gusmaroli, G., Latorre, A., Malaguti, M. C., Marano, M., Marano, P., Marconi, R., Mazzucchi, S., Meco, G., Minafra, B., Morgante, F., Pacchetti, C., Pierantozzi, M., Pontieri, F. E., Riboldazzi, G., Ricchi, V., Ricchieri, G., Rinaldo, S., Rispoli, V., Rossi, S., Rubino, A., Russo, A., Saddi, M. V., Stefani, A., Simoni, S., Solla, P., Tambasco, N., Tamburin, S., Tessitore, A., Torre, E., Ulivelli, M., Vita M., Gi, Volonté, M. A., on behalf of the, ITALIAN LEVODOPA CARBIDOPA INTESTINAL GEL WORKING GROUP, Sensi, M., Cossu, G., Mancini, F., Pilleri, M., Zibetti, M., Modugno, N., Quatrale, R., Tamma, F., Antonini, A., Aguggia, M., Amboni, M., Arca, R., Bartolomei, L., Bonetto, N., Calandra-Buonaura, G., Bove, F., Calandrella, D., Canesi, M., Cannas, A., Capecci, M., Caputo, E., Ceravolo, M. G., Ceravolo, R., Cerrone, G., Coletti Moja, M., Comi, C., Cortelli, P., D'Antonio, P., Dematteis, F., Di Lazzaro, V., Eleopra, R., Fabbrini, G., Fichera, M., Grassi, E., Guido, M., Gusmaroli, G., Latorre, A., Malaguti, M. C., Marano, M., Marano, P., Marconi, R., Mazzucchi, S., Meco, G., Minafra, B., Morgante, F., Pacchetti, C., Pierantozzi, M., Pontieri, F. E., Riboldazzi, G., Ricchi, V., Ricchieri, G., Rinaldo, S., Rispoli, V., Rossi, S., Rubino, A., Russo, A., Saddi, M. V., Stefani, A., Simoni, S., Solla, P., Tambasco, N., Tamburin, S., Tessitore, A., Torre, E., Ulivelli, M., Vita, M. G., Volonte, M. A., Sensi, Mariachiara, Cossu, Giovanni, Mancini, Francesca, Pilleri, Manuela, Zibetti, Maurizio, Modugno, Nicola, Quatrale, Rocco, Tamma, Filippo, Antonini, Angelo, Italian Levodopa Carbidopa Intestinal Gel Working Group [.., Calandra-Buonaura, Giovanna, Cortelli, Pietro, and ]
- Subjects
Male ,0301 basic medicine ,Pediatrics ,Neurology ,Parkinson's disease ,Longitudinal Studie ,Pharmacology ,Antiparkinson Agents ,Levodopa ,0302 clinical medicine ,Retrospective Studie ,Weight loss ,Drug Combination ,levodopa-carbidopa intestinal gel infusion ,neuropathy ,parkinson's disease ,withdrawal ,Longitudinal Studies ,Gel ,Carbidopa ,Parkinson Disease ,Health Survey ,Intestine ,Substance Withdrawal Syndrome ,Intestines ,Drug Combinations ,Italy ,Antiparkinson Agent ,Withdrawal ,Disease Progression ,Female ,Settore MED/26 - Neurologia ,medicine.symptom ,Human ,medicine.drug ,medicine.medical_specialty ,Levodopa-carbidopa intestinal gel infusion ,Neuropathy ,Geriatrics and Gerontology ,Neurology (clinical) ,03 medical and health sciences ,medicine ,Humans ,Adverse effect ,Retrospective Studies ,business.industry ,Retrospective cohort study ,Gels ,Health Surveys ,medicine.disease ,Comorbidity ,Discontinuation ,030104 developmental biology ,business ,030217 neurology & neurosurgery - Abstract
Objectives To report the results of a national survey aimed at quantifying the current level of diffusion of Levodopa/carbidopa intestinal gel (LCIG) in Italy. Methods Sixty Parkinson's Disease (PD) specialists in Italy were invited to complete a survey covering issues on clinical and practical aspects of LCIG therapy. Results Clinical features of 905 patients were collected retrospectively. The majority of centres reported the use of a multidisciplinary team, biochemistry testing, neurophysiological and neuropsychological tests before and after treatment, in addition to caregivers' training and patient's follow as outpatients. Most centres (60%) used internal guidelines for patient selection. The overall rate of adverse events was 55.1%. Weight loss, chronic polyneuropathy and stoma infection were the most frequently reported. 40% of centres used replacement therapy with Vitamin B12 and Folic acid from the start of LCIG and continued this for the duration of treatment. The rate of discontinuation was of 25.7% overall, with 9.5% of cases occurring in the first year. The main causes of withdrawal were device-related complications, disease progression (comorbidity, severe dementia) and caregiver and/or patient dissatisfaction. Conclusions In Italy LCIG infusion is managed in a uniform manner at a clinical, practical and organizational level even though the selection criteria are not standardized through the country. The high percentage of patients remaining on treatment in the short- and long-term follow-up confirms effectiveness of treatment, careful follow-up, and appropriate patient and caregivers training.
- Published
- 2017
19. Cerebral vasomotor reactivity in de novo unilateral Parkinson's disease: a comparison of hemodynamic parameters among affected and healthy hemisphere
- Author
-
Rocco, A., Vicenzini, E., Mercuri, N. B., Pierantozzi, M., and MARINA DIOMEDI
- Subjects
Settore MED/26 - Published
- 2018
20. malattia di alzheimer e altre demenze diagnosi e terapia integrata
- Author
-
Pierantozzi, M and Scaricamazza, E
- Subjects
Settore MED/26 - Neurologia - Published
- 2017
21. Deterioramento cognitivo nelle sinucleinopatie
- Author
-
Pierantozzi, M and Scaricamazza, E
- Subjects
Settore MED/26 - Neurologia - Published
- 2017
22. Clinical variables associated with treatment changes in Parkinson’s disease: results from the longitudinal phase of the REASON study
- Author
-
Abbruzzese, Giovanni, Barone, Paolo, Ceravolo, Roberto, Fabbrini, Giovanni, Lessi, Patrizia, Ori, Alessandra, Simoni, Lucia, Tinazzi, Michele, Antonini, Angelo, Melone, MAB, Schettino, C, Capaldo, G, Iemolo, F, Sanzaro, E, Ceravolo, MG, Capecci, M, Andrenelli, E, Pontieri, FE, Pellicano, C, Benincasa, D, Fabbrini, G, Pietracupa, S, Latorre, A, Tedeschi, G, Tessitore, A, Giordano, A, Bonuccelli, U, Frosini, D, Vanelli, F, Comi, G, Volonté, MA, Spagnolo, F, Scaglioni, A, Abrignani, G, Abbruzzese, G, Avanzino, L, Tamburini, T, Antonini, A, Facchini, S, Biundo, R, Altavista, MC, Roberti, C, Avarello, T, Bono, G, Riboldazzi, G, Leva, S, Del Sette, M, Carabelli, E, Traverso, E, Michelucci, R, Nassetti, S, Pasini, E, Padovani, A, Cottini, E, Bigni, B, Ruggieri, S, Modugno, N, Fischetti, M, Stefani, A, Pierantozzi, M, Stampanoni Bassi, M, Tinazzi, M, Ottaviani, S, Ajena, D, Trianni, G, Caggiula, M, Valenti, G, My, F, Grioli, S, La Farina, I, Zambito Marsala, S, Marchini, C, Gioulis, M, Asteggiano, G, L’Episcopo, MR, Saracco, E, Barone, P, Picillo, M, Moccia, M, Onofrj, M, Thomas, A, Denaro, A, Marini, C, De Santis, F, Spagnoli, V, L’Erario, R, Passadore, P, Belgrado, E, Mucchiut, M, Priori, A, Cogiamanian, F, Marchet, A., Abbruzzese, Giovanni, Barone, Paolo, Ceravolo, Roberto, Fabbrini, Giovanni, Lessi, Patrizia, Ori, Alessandra, Simoni, Lucia, Tinazzi, Michele, Antonini, Angelo, Melone, Mab, Schettino, C, Capaldo, G, Iemolo, F, Sanzaro, E, Ceravolo, Mg, Capecci, M, Andrenelli, E, Pontieri, Fe, Pellicano, C, Benincasa, D, Fabbrini, G, Pietracupa, S, Latorre, A, Tedeschi, G, Tessitore, A, Giordano, A, Bonuccelli, U, Frosini, D, Vanelli, F, Comi, G, Volonté, Ma, Spagnolo, F, Scaglioni, A, Abrignani, G, Abbruzzese, G, Avanzino, L, Tamburini, T, Antonini, A, Facchini, S, Biundo, R, Altavista, Mc, Roberti, C, Avarello, T, Bono, G, Riboldazzi, G, Leva, S, Del Sette, M, Carabelli, E, Traverso, E, Michelucci, R, Nassetti, S, Pasini, E, Padovani, A, Cottini, E, Bigni, B, Ruggieri, S, Modugno, N, Fischetti, M, Stefani, A, Pierantozzi, M, Stampanoni Bassi, M, Tinazzi, M, Ottaviani, S, Ajena, D, Trianni, G, Caggiula, M, Valenti, G, My, F, Grioli, S, La Farina, I, Zambito Marsala, S, Marchini, C, Gioulis, M, Asteggiano, G, L’Episcopo, Mr, Saracco, E, Barone, P, Picillo, M, Moccia, M, Onofrj, M, Thomas, A, Denaro, A, Marini, C, De Santis, F, Spagnoli, V, L’Erario, R, Passadore, P, Belgrado, E, Mucchiut, M, Priori, A, Cogiamanian, F, and Marchet, A.
- Subjects
Male ,medicine.medical_specialty ,Clinical variables ,Neurology ,Parkinson's disease ,Motor symptoms ,Non-motor symptoms ,Parkinson’s disease ,Treatment persistence ,Aged ,Female ,Humans ,Longitudinal Studies ,Middle Aged ,Parkinson Disease ,Physician's Role ,Severity of Illness Index ,Treatment Outcome ,Neurology (clinical) ,Psychiatry and Mental Health ,2708 ,Longitudinal Studie ,Dermatology ,Disease ,Internal medicine ,motor symptoms,non-motor symptoms ,Parkinson’s disease,treatment persistence ,Severity of illness ,Medicine ,Neuroradiology ,business.industry ,musculoskeletal, neural, and ocular physiology ,General Medicine ,medicine.disease ,nervous system diseases ,cardiovascular system ,Physical therapy ,Neurosurgery ,business ,Human - Abstract
To assess over a period of 9 months in a sample of Italian Parkinson’s disease (PD) patients reasons leading the neurologist to modify dopaminergic treatment and patients’ causes of dissatisfaction with ongoing therapy. To evaluate the influence of disease severity on therapy persistence. A disease severity balanced sample of PD patients with stable anti-parkinsonian drugs (APD) treatment was enrolled and evaluated every 3 months. Patients requiring APD treatment modifications were discontinued from the study. The probability to modify APD treatment is greater for higher motor (UPDRS scores) and non-motor symptoms (NMSS score) severity. Both from neurologist’s and patient’s perspective, motor symptoms were the main determinants underlying APD treatment modifications. Non-motor symptoms were cause of dissatisfaction with ongoing APD treatment for 52 % of the patients, while only 36 % of the neurologists considered these as valid reasons for therapy change. REASON is the first study in PD patients that prospectively examined reasons driving APD treatment changes. Results show that the disease severity significantly increases the probability of APD treatment change. Patients attribute greater relevance than neurologists to non-motor symptoms as reason requiring treatment changes. This confirms that patient and neurologist perceptions only partially overlap.
- Published
- 2015
23. Corrigendum to “Dopaminergic involvement in a drummer with focal dystonia: A case study” [Clin. Neurol. Neurosurg. (2018) 166 (March) 54–55]
- Author
-
Schirinzi, T., primary, Scalise, S., additional, Di Lazzaro, G., additional, Cerroni, R., additional, Chiaravalloti, A., additional, Lavorenti Figueras, P., additional, Pierantozzi, M., additional, Pisani, A., additional, and Stefani, A, additional
- Published
- 2018
- Full Text
- View/download PDF
24. A naturalistic observation on 20 consecutive patients under LCIG at the “Tor Vergata” University; enforced counseling and alternative route of LD delivery for avoiding discontinuation?
- Author
-
Cerroni, R.E., primary, Imbriani, P., additional, Scalise, S., additional, Pierantozzi, M., additional, Pisani, A., additional, and Stefani, A., additional
- Published
- 2018
- Full Text
- View/download PDF
25. Artificial Neural Network Modeling of Liquid Thermal Conductivity for alkanes, ketones and silanes
- Author
-
Latini, G, primary, Nicola, G Di, additional, Pierantozzi, M, additional, Coccia, G, additional, and Tomassetti, S, additional
- Published
- 2017
- Full Text
- View/download PDF
26. Experimental characterization of a solar cooker with thermal energy storage based on solar salt
- Author
-
Coccia, G, primary, Nicola, G Di, additional, Tomassetti, S, additional, Gabrielli, G, additional, Chieruzzi, M, additional, and Pierantozzi, M, additional
- Published
- 2017
- Full Text
- View/download PDF
27. Equation for the Thermal Conductivity of Liquids and an Artificial Neural Network
- Author
-
Di Nicola, G., primary, Pierantozzi, M., additional, Petrucci, G., additional, and Stryjek, R., additional
- Published
- 2016
- Full Text
- View/download PDF
28. Restless legs syndrome and post polio syndrome: a case−control study
- Author
-
Romigi, A., primary, Pierantozzi, M., additional, Placidi, F., additional, Evangelista, E., additional, Albanese, M., additional, Liguori, C., additional, Nazzaro, M., additional, Risina, B. U., additional, Simonelli, V., additional, Izzi, F., additional, Mercuri, N. B., additional, and Desiato, M. T., additional
- Published
- 2014
- Full Text
- View/download PDF
29. Deep brain stimulation in Parkinson's disease patients and routine 6-OHDA rodent models: Synergies and pitfalls
- Author
-
Mariangela Pierantozzi, Vincenza D'Angelo, Alessandro Stefani, Matteo Spanetta, Salvatore Galati, Laura Clara Grandi, Rocco Cerroni, Stefani, A, Cerroni, R, Pierantozzi, M, D'Angelo, V, Grandi, L, Spanetta, M, and Galati, S
- Subjects
Deep brain stimulation ,Parkinson's disease ,medicine.medical_treatment ,Deep Brain Stimulation ,Thalamus ,Rodentia ,6-OHDA ,subthalamic nucleu ,Settore MED/05 ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Dopamine ,Subthalamic Nucleus ,Basal ganglia ,medicine ,Animals ,Humans ,neuronal oscillation ,Oxidopamine ,MPTP ,030304 developmental biology ,0303 health sciences ,business.industry ,General Neuroscience ,Glutamate receptor ,Parkinson Disease ,medicine.disease ,Subthalamic nucleus ,chemistry ,beta band ,business ,Neuroscience ,030217 neurology & neurosurgery ,medicine.drug - Abstract
The history of deep brain stimulation for Parkinson's disease (PD) represented a paradigmatic cross-talk between mammalian disease models and clinical evidence in humans. Fascinating were the results achieved by high frequency stimulation (HFS) into the subthalamic nucleus (STN) of MPTP-treated primates. An analogous strategy relieved tremor and hypokinetic parameters in PD patients. The 6-hydroxydopamine (6-OHDA) rodent model has mastered decades of research, contributing to understanding of the PD pathology. However, this review wonders about the actual synergy between the routine neurotoxic models and PD patients underlying STN-DBS. At first, some findings collected following 6-OHDA, promoted dogmatic visions, as the wrong contention that suppression of STN glutamate was the key therapeutic player. Instead, changes of glutamate release are negligible in humans during transition to ON-state. Besides, the imbalance of basal ganglia endogenous band frequencies, the beta (β) band increase and the cortical-basal ganglia synchronization, undisputedly shared by models and PD patients, do not govern the whole spectrum of non-motor PD signs, difficult to investigate in rodents. Furthermore, the tonic release of dopamine, inferred during HFS in rodents, was not replicated in humans. Finally, neurotoxic rodent models describe a 'pure' dopamine depletion sparing pathways crucial in parkinsonian phenotypes, that is, noradrenergic and cholinergic ones. Although the utilization of neurotoxic models is still providing major advancements, we pore over these contradictions and try to support possible amendments of neurotoxic models (advocating modern 'in vivo' approaches and recordings extending towards motor thalamus) for pursing the development of new DBS technology.
- Published
- 2021
30. Safinamide effect on sleep architecture of motor fluctuating Parkinson's disease patients: A polysomnographic rasagiline-controlled study.
- Author
-
Bovenzi R, Conti M, Pierantozzi M, Testone G, Fernandes M, Manfredi N, Schirinzi T, Cerroni R, Mercuri NB, Stefani A, and Liguori C
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Prospective Studies, Monoamine Oxidase Inhibitors pharmacology, Monoamine Oxidase Inhibitors administration & dosage, Antiparkinson Agents administration & dosage, Antiparkinson Agents pharmacology, Sleep drug effects, Sleep physiology, Parkinson Disease drug therapy, Parkinson Disease physiopathology, Parkinson Disease complications, Alanine analogs & derivatives, Alanine pharmacology, Alanine administration & dosage, Polysomnography, Sleep Wake Disorders drug therapy, Sleep Wake Disorders etiology, Indans pharmacology, Indans administration & dosage, Benzylamines pharmacology, Benzylamines administration & dosage
- Abstract
Introduction: Sleep problems commonly occur in Parkinson's disease (PD) and significantly affect patients' quality of life. A possible effect on subjective sleep disturbances of monoamine oxidase-B inhibitors (MAOB-Is) has been described., Methods: This prospective, observational, single-centre study involved 45 fluctuating PD patients complaining sleep problems as documented by the PD Sleep Scale -2nd version (PDSS-2 ≥18) starting rasagiline 1 mg/daily or safinamide 100 mg/daily, according to common clinical practice, and maintaining antiparkinsonian therapy unchanged. Polysomnography (PSG), sleep questionnaires (PDSS-2, Epworth Sleepiness Scale - ESS), and motor function were evaluated at baseline (T0) and after 4 months of treatment (T1)., Results: Safinamide was prescribed in thirty patients and rasagiline in fifteen patients. Both drugs induced a significant improvement in Movement Disorder Society Unified PD Rating Scale III scores. Patients treated with rasagiline showed a significant increase in stage 1 (N1) Non-REM sleep compared to T0, with no significant effects on sleep scales. Patients treated with safinamide showed a significant increase in stage 3 of Non-REM sleep and sleep efficiency and a reduction in the rate of periodic limb movements, matching a significant reduction in PDSS-2 and ESS scales compared to T0., Conclusion: This study showed that safinamide, in addition to having a significant effect on PD motor symptoms, like the other MAOB-Is, may exert a specific beneficial effect on subjective and objective sleep, probably driven by its dual mechanism of action, which involves both dopaminergic and glutamatergic neurotransmission., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
31. Immunometabolic Signature and Tauopathy Markers in Blood Cells of Progressive Supranuclear Palsy.
- Author
-
Rosina M, Veltri F, Nesci V, Bissacco J, Bovenzi R, Mascioli D, Simonetta C, Zenuni H, Maftei D, Marano M, Pierantozzi M, Stefani A, Chiurchiù V, Longone P, Valle C, Mercuri NB, Ferri A, and Schirinzi T
- Abstract
Background: Peripheral immune cells critically contribute to the clinical-pathological progression of neurodegenerative diseases and also represent a reliable frame for translational applications. However, data on progressive supranuclear palsy (PSP) are almost scarce in this regard., Objective: Our goal is to provide a broad biological characterization of peripheral immune cells in a selected PSP cohort., Methods: Seventy-one PSP patients scored on the PSP Rating Scale (PSPRS), and 59 controls were enrolled. The blood cell count was collected, together with the neutrophil-to-lymphocyte ratio (NLR) calculation. In a subgroup of patients and controls, the peripheral blood mononuclear cells (PBMCs) were analyzed by the mitochondrial bioenergetic performance and the western blot assay of the nuclear factor erythroid 2-related factor (NRF2)/heme oxygenase 1 (HO-1) pathway and the total tau (t-tau) and phosphorylated tau (p-tau) proteins. Case-control comparison and correlation analyses were performed., Results: PSP patients had a NLR higher than controls, with increased circulating neutrophils. The leukocyte metabolism was also globally increased and the NRF2/HO-1 pathway activated in patients. P-tau, but not t-tau, significantly accumulated in PSP PBMCs and inversely correlated with the PSPRS., Conclusions: PSP displays a systemic inflammatory shift of the peripheral immunity, which may justify a metabolic reprogramming of the blood leukocytes. Consistently, the NRF2/HO-1 pathway, a master regulator of inflammatory and metabolic response, was activated. PBMCs also engulf tau proteins, especially p-tau, in a way inverse to the disease severity, allowing for a peripheral tracking of tauopathy in patients. Immunometabolic targets may, therefore, gain relevance to PSP in biomarker or therapeutic purposes. © 2024 International Parkinson and Movement Disorder Society., (© 2024 International Parkinson and Movement Disorder Society.)
- Published
- 2024
- Full Text
- View/download PDF
32. Hearing dysfunction heralds an increase in non-motor burden and a worse quality of life in Parkinson's disease: new insights from non-motor spectrum.
- Author
-
Garasto E, Stefani A, Pierantozzi M, Conti M, Moleti A, Sisto R, Viziano A, Liguori C, Schirinzi T, Mercuri NB, and Cerroni R
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Audiometry, Pure-Tone, Hearing Loss physiopathology, Hearing Loss etiology, Cost of Illness, Surveys and Questionnaires, Otoacoustic Emissions, Spontaneous physiology, Severity of Illness Index, Parkinson Disease complications, Parkinson Disease physiopathology, Quality of Life
- Abstract
Background: Sensorial non-motor symptoms (NMSs) in Parkinson's disease (PD) still lack appropriate investigation in clinical practice. This study aimed to assess if and to what extent auditory dysfunction is associated with other NMSs in PD and its impact on patient's quality of life (QoL)., Methods: We selected patients with idiopathic PD, without other concomitant neurological diseases, dementia, or diagnosis of any audiological/vestibular disease. Demographic and clinical data were collected. Patients underwent otoscopic examination, audiological testing with pure tone audiometry (PTA) and distortion product otoacoustic emissions (DPOAEs) and completed Non-Motor Symptoms Scale (NMSS) and Parkinson's Disease Questionnaires-39 (PDQ-39). ANCOVA and partial correlation analysis have been used for statistical analysis., Results: 60 patients were enrolled and completed PTA and DPOAEs. 32 patients with hearing impairment (HI), assessed by PTA, (hearing threshold ≥ 25 dB) showed similar disease duration, motor impairment, and staging, compared to patients without HI, but higher scores both in NMSS and in PDQ-39, except for cardiovascular (CV), gastrointestinal (GI), urogenital (U) and sexual function (SF) of NMSS. In addition, DPOAEs showed a significant correlation with higher scores both in NMSS and PDQ-39, except for CV, SF, GI, U and perceptual problem subdomains of NMSS., Conclusion: This study demonstrated that PD patients with HI have a greater burden of NMS and lower related QoL and functioning. Our results highlight the importance to reconsider HI as a NMS, in parallel with the others. HI evaluation, even in asymptomatic patients, may reveal a wider pathology with a worse QoL., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
33. Rare association between spinocerebellar ataxia and amyotrophic lateral sclerosis: a case series.
- Author
-
Ferrari V, Conti M, Bovenzi R, Cerroni R, Pierantozzi M, Mercuri NB, and Stefani A
- Subjects
- Humans, Male, Middle Aged, Trinucleotide Repeat Expansion genetics, Amyotrophic Lateral Sclerosis genetics, Amyotrophic Lateral Sclerosis diagnosis, Amyotrophic Lateral Sclerosis complications, Spinocerebellar Ataxias genetics, Spinocerebellar Ataxias complications, Spinocerebellar Ataxias physiopathology, Ataxin-2 genetics
- Abstract
Introduction: In this work, we describe a new case of association between SCA2 and MND., Case Report: A 58-year-old man who was diagnosed with spinocerebellar ataxia type 2 presented dysphagia and a significant decline in his ability to walk, with a reduction in autonomy and the need to use a wheelchair. We performed electromyography and electroneurography of the four limbs and of the cranial district and motor-evoked potentials to study upper and lower motor neurons. Referring to the revised El Escorial criteria of 2015, ALS diagnosis was made., Discussion: Considering different cases described in literature over the years, SCA2 could represent an important risk factor for developing ALS. In particular, the presence of alleles of ATXN2 with 27 and 28 CAG repeats seems to slightly decrease the risk of developing the disease, which would instead be progressively increased by the presence of alleles with 29, 30, 31, 32, and 33 repeats. The exact physiopathological mechanism by which the mutation increases the risk of developing the disease is currently unknown. Transcriptomic studies on mouse models have demonstrated the involvement of several pathways, including the innate immunity regulation by STING and the biosynthesis of fatty acid and cholesterol by SREBP., Conclusion: CAG repeat expansions in the ATXN2 gene have been associated with variable neurological presentations, which include SCA2, ALS, Parkinsonism, or a combination of them. Further research is needed to understand the relationship between SCA2 and ALS better and explore molecular underlying mechanisms., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
34. Contribution of testosterone and estradiol in sexual dimorphism of early-onset Parkinson's disease.
- Author
-
Bovenzi R, Conti M, Simonetta C, Bissacco J, Mascioli D, Michienzi V, Pieri M, Cerroni R, Liguori C, Pierantozzi M, Stefani A, Mercuri NB, and Schirinzi T
- Abstract
Early-onset Parkinson's disease (EOPD) occurs during the fertile life, when circulating neuroactive sex hormones might enhance the sexual dimorphism of the disease. Here, we aimed to examine how sex hormones can contribute to sex differences in EOPD patients. A cohort of 34 EOPD patients, 20 males and 14 females, underwent comprehensive clinical evaluation of motor and non-motor disturbances. Blood levels of estradiol, total testosterone, follicle-stimulating hormone, and luteinizing hormone were measured in all patients and correlated to clinical features. We found that female patients exhibited greater non-motor symptoms and a relatively higher rate of dystonia than males. In females, lower estradiol levels accounted for higher MDS-UPDRS-II and III scores and more frequent motor complications, while lower testosterone levels were associated with a major occurrence of dystonia. In male patients, no significant correlations emerged. In conclusion, this study highlighted the relevance of sex hormone levels in the sexual dimorphism and unique phenotype of EOPD., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
35. Insular and limbic abnormal functional connectivity in early-stage Parkinson's disease patients with autonomic dysfunction.
- Author
-
Conti M, Garasto E, Bovenzi R, Ferrari V, Mercuri NB, Di Giuliano F, Cerroni R, Pierantozzi M, Schirinzi T, Stefani A, and Rocchi C
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Insular Cortex diagnostic imaging, Insular Cortex physiopathology, Limbic System physiopathology, Limbic System diagnostic imaging, Neural Pathways physiopathology, Neural Pathways diagnostic imaging, Parkinson Disease physiopathology, Parkinson Disease diagnostic imaging, Parkinson Disease complications, Autonomic Nervous System Diseases physiopathology, Autonomic Nervous System Diseases etiology, Electroencephalography
- Abstract
Autonomic symptoms in Parkinson's disease result from variable involvement of the central and peripheral systems, but many aspects remain unclear. The analysis of functional connectivity has shown promising results in assessing the pathophysiology of Parkinson's disease. This study aims to investigate the association between autonomic symptoms and cortical functional connectivity in early Parkinson's disease patients using high-density EEG. 53 early Parkinson's disease patients (F/M 18/35) and 49 controls (F/M 20/29) were included. Autonomic symptoms were evaluated using the Scales for Outcomes in Parkinson's disease-Autonomic Dysfunction score. Data were recorded with a 64-channel EEG system. We analyzed cortical functional connectivity, based on weighted phase-lag index, in θ-α-β-low-γ bands. A network-based statistic was used to perform linear regression between Scales for Outcomes in Parkinson's disease-Autonomic Dysfunction score and functional connectivity in Parkinson's disease patients. We observed a positive relation between the Scales for Outcomes in Parkinson's disease-Autonomic Dysfunction score and α-functional connectivity (network τ = 2.8, P = 0.038). Regions with higher degrees were insula and limbic lobe. Moreover, we found positive correlations between the mean connectivity of this network and the gastrointestinal, cardiovascular, and thermoregulatory domains of Scales for Outcomes in Parkinson's disease-Autonomic Dysfunction. Our results revealed abnormal functional connectivity in specific areas in Parkinson's disease patients with greater autonomic symptoms. Insula and limbic areas play a significant role in the regulation of the autonomic system. Increased functional connectivity in these regions might represent the central compensatory mechanism of peripheral autonomic dysfunction in Parkinson's disease., (© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
36. A biological characterization of patients with postmenopausal Parkinson's disease.
- Author
-
Bovenzi R, Schirinzi T, Conti M, Sancesario GM, Zenuni H, Simonetta C, Bissacco J, Mascioli D, Pieri M, Cerroni R, Stefani A, Mercuri NB, and Pierantozzi M
- Subjects
- Humans, Female, Middle Aged, Aged, Amyloid beta-Peptides cerebrospinal fluid, Amyloid beta-Peptides blood, Estradiol blood, alpha-Synuclein blood, alpha-Synuclein cerebrospinal fluid, Follicle Stimulating Hormone blood, Follicle Stimulating Hormone cerebrospinal fluid, Testosterone blood, Testosterone cerebrospinal fluid, Peptide Fragments cerebrospinal fluid, Peptide Fragments blood, Biomarkers blood, Biomarkers cerebrospinal fluid, Luteinizing Hormone blood, Luteinizing Hormone cerebrospinal fluid, Parkinson Disease blood, Parkinson Disease cerebrospinal fluid, Postmenopause blood, tau Proteins cerebrospinal fluid, tau Proteins blood
- Abstract
Menopause increases the risk for Parkinson's disease (PD), although the underlying biological mechanisms have not been established in patients. Here, we aimed to understand the basis of menopause-related vulnerability to PD. Main motor and non-motor scores, blood levels of estradiol, testosterone, follicle-stimulating hormone, and luteinizing hormone, CSF levels of total α-synuclein, amyloid-β-42, amyloid-β-40, total tau, and phosphorylated-181-tau were examined in 45 women with postmenopausal-onset PD and 40 age-matched controls. PD patients had higher testosterone and lower estradiol levels than controls, and the residual estradiol production was associated with milder motor disturbances and lower dopaminergic requirements. In PD but not in controls, follicle-stimulating hormone levels correlated with worse cognitive scores and CSF markers of amyloidopathy and neuronal loss. In conclusion, menopause-related hormonal changes might differentially contribute to clinical-pathological trajectories of PD, accounting for the peculiar vulnerability to the disease., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.)
- Published
- 2024
- Full Text
- View/download PDF
37. Brainstem impairment in obstructive sleep apnoea and the effect of CPAP treatment: an electrophysiological blink reflex study.
- Author
-
Liguori C, Fernandes M, Spanetta M, Zanovello M, Giambrone MP, Lupo C, Placidi F, Izzi F, Mercuri NB, and Pierantozzi M
- Subjects
- Humans, Male, Middle Aged, Female, Adult, Aged, Continuous Positive Airway Pressure, Sleep Apnea, Obstructive therapy, Sleep Apnea, Obstructive physiopathology, Blinking physiology, Brain Stem physiopathology, Polysomnography
- Abstract
Purpose: This study aimed to evaluate the functionality of the brainstem structures through the blink reflex (BR) test in patients with obstructive sleep apnoea (OSA) and to assess the effects of continuous positive airway pressure (CPAP) treatment on BR responses., Methods: Patients with moderate-severe OSA and controls underwent BR testing. Patients with OSA who were adherent to CPAP therapy repeated BR testing at 6 months follow-up. CPAP adherence was defined as CPAP use for ≥ 4 hour per night on > 5 nights per week with residual apnoea-hypopnea index less than 5 events per hour., Results: A total of 22 patients with OSA (86% male, mean age 57.8 ± 10.6 years) and 20 controls (60% male, mean age 55.3 ± 9.3 years) were included. Patients with OSA showed longer right and left R1 latency, as well as delayed right ipsilateral and contralateral R2 latencies compared to controls. Patients with OSA who were compliant with CPAP treatment (n = 16; 88% men, mean age 58.8 ± 9.7 years) showed a significant decrease in latency of the right ipsilateral and contralateral R2 responses at 6 months., Conclusion: This study showed an abnormal pattern of BR responses in patients with OSA, consistent with a significant impairment of brainstem functionality in OSA. CPAP treatment partially improved the BR responses, suggesting the importance of treating OSA., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
38. Sex differences in Parkinson's disease-related non motor symptoms: a focus on sleep problems.
- Author
-
Bovenzi R, Conti M, De Franco V, Pierantozzi M, Schirinzi T, Cerroni R, Stefani A, Mercuri NB, and Liguori C
- Abstract
Parkinson's disease (PD) symptomatology differs between females and males, yet the contribution of sex on sleep problems needs further analysis. Here, we aimed to investigate sex-specific patterns in the relationship between sleep problems, assessed using the Parkinson's disease sleep scale (PDSS-2), non motor symptoms (NMS), measured by the NMS scale (NMSS), and health-related quality of life (HR-QoL), evaluated by the Parkinson's disease questionnaire (PDQ-39), in a large cohort of PD patients. One-hundred-fifty-four PD patients were included in the study. Female PD patients (n = 62) exhibited a higher prevalence of sleep problems than males (n = 92), with nocturnal motor-related sleep issues being the most frequent. Sleep disturbances differently correlated with a range of NMS between the two sexes. In females, sleep problems mostly correlated with pain; on the other hand, sleep disturbances were linked to a frailer phenotype characterized by global dysautonomia, perception disturbances, and impaired cognitive function in males. Whether female PD patients experienced a lower HR-QoL than males, sleep disturbances were associated with a worse HR-QoL in both sexes. In conclusion, sleep problems in PD differently burden the two sexes, suggesting possible different etiopathogenesis, diagnostic investigations, and possibly tailored approaches., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
39. Assessment of Psychometric Characteristics of Parkinson's Disease Sleep Scale 2 and Analysis of a Cut-Off Score for Detecting Insomnia in Italian Patients with Parkinson's Disease: A Validation Study.
- Author
-
Liguori C, Frontani F, Francescangeli G, Pierantozzi M, Cerroni R, Schirinzi T, Stefani A, Mercuri NB, and Galeoto G
- Abstract
Introduction: Sleep disorders are frequent non-motor symptoms affecting patients with Parkinson's disease (PD). Insomnia represents the most common sleep disorder. Parkinson's disease Sleep Scale 2 (PDSS-2) is a specific tool to investigate sleep problems in PD. The General Sleep Disturbances Scale (GSDS) was a general scale validated for the Italian population. Our goal was to assess the psychometric characteristics of PDSS-2 and the GSDS in this population, calculating a cut-off score for insomnia symptoms by using subitems of PDSS-2., Methods: Patients admitted at the PD Unit of the Hospital of Rome Tor Vergata outpatient clinic and those afferent to PD associations were asked to complete PDSS-2 and GSDS to be correlated to identify a cut-off for insomnia symptoms. Items 1,2,3,8,13 of PDSS-2 were used to detect insomnia. An ROC curve to assess a cut-off score for insomnia was determined. A cross-cultural analysis of PD population characteristics was performed., Results: In total, 350 PD patients were recruited. Cronbach's alpha was high for the total score (0.828 for PDSS-2 and 0.832 for GSDS). A cross-cultural analysis did not show any significant p -value. The ROC curve yielded an AUC of 0.79 (CI: 0.75-0.84). The cut-off value for insomnia disorder based on items 1,2,3,8,13 of PDSS-2 was >10, demonstrating a sensitivity of 76% and a specificity of 69% in determining the presence of subjective insomnia symptoms in PD., Discussion: PDSS-2 is demonstrated to be a valid, specific tool to address sleep disturbances in PD patients. A cut-off score of 10 for items 1,2,3,8,13 was identified for detecting insomnia symptoms in PD patients.
- Published
- 2024
- Full Text
- View/download PDF
40. Parkinson's disease motor progression in relation to the timing of REM sleep behavior disorder presentation: an exploratory retrospective study.
- Author
-
Bovenzi R, Pierantozzi M, Conti M, Carignani S, Fernandes M, Schirinzi T, Cerroni R, Mercuri NB, Stefani A, and Liguori C
- Subjects
- Humans, Retrospective Studies, Levodopa, Longitudinal Studies, Parkinson Disease complications, Parkinson Disease drug therapy, Parkinson Disease epidemiology, REM Sleep Behavior Disorder diagnosis, REM Sleep Behavior Disorder etiology
- Abstract
REM sleep behavior disorder (RBD) is a frequent non-motor symptom of Parkinson's disease (PD), and the timing of its presentation might have a role in the underlying neurodegenerative process. Here, we aimed to define the potential impact of probable RBD (pRBD) on PD motor progression.We conducted a longitudinal retrospective study on 66 PD patients followed up at the University Hospital of Rome Tor Vergata. Patients were divided into three groups: with post-motor pRBD (pRBD
post , n = 25), without pRBD (pRBDwo , n = 20), and with pre-motor pRBD (pRBDpre , n = 21). Hoehn and Yahr (H&Y) scores, Unified PD Rating Scale (UPDRS) motor scores, and levodopa equivalent daily dose were collected at two follow-up visits conducted in a 5-year interval (T0 and T1). pRBDpost patients had a greater rate of motor progression in terms of the H&Y scale compared to pRBDpre and pRBDwo patients, without the influence of anti-parkinsonian treatment.These preliminary findings suggest that the post-motor occurrence of pRBD can be associated with an acceleration in PD motor progression., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
41. Motor cortex transcranial direct current stimulation improves non-motor symptoms in early-onset Parkinson's disease: a pilot study.
- Author
-
Simonetta C, Bissacco J, Conti M, Bovenzi R, Salimei C, Cerroni R, Pierantozzi M, Stefani A, Mercuri NB, and Schirinzi T
- Subjects
- Humans, Pilot Projects, Quality of Life, Cross-Over Studies, Double-Blind Method, Motor Cortex physiology, Parkinson Disease complications, Parkinson Disease therapy, Transcranial Direct Current Stimulation adverse effects
- Abstract
Early-onset Parkinson's Disease (EOPD) demands tailored treatments. The younger age of patients might account for a higher sensitivity to transcranial direct current stimulation (tDCS) based non-invasive neuromodulation, which may raise as an integrative therapy in the field. Accordingly, here we assessed the safety and efficacy of the primary left motor cortex (M1) anodal tDCS in EOPD. Ten idiopathic EOPD patients received tDCS at 2.0 mA per 20 min for 10 days within a crossover, double-blind, sham-controlled pilot study. The outcome was evaluated by measuring changes in MDS-UPDRS part III, Non-Motor Symptoms Scale (NMSS), PD-cognitive rating scale, and PD Quality of Life Questionnaire-39 scores. We showed that anodal but not sham tDCS significantly reduced the NMSS total and "item 2" (sleep/fatigue) scores. Other parameters were not modified. No adverse events occurred. M1 anodal tDCS might thus evoke plasticity changes in cortical-subcortical circuits involved in non-motor functions, supporting the value as a therapeutic option in EOPD., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
42. Pregnancy, fertile life factors, and associated clinical course in PRKN early-onset Parkinson's disease.
- Author
-
Bovenzi R, Conti M, Degoli GR, Cerroni R, Artusi CA, Pierantozzi M, Stefani A, Mercuri NB, and Schirinzi T
- Subjects
- Female, Humans, Pregnancy, Disease Progression, Mutation, Ubiquitin-Protein Ligases genetics, Parkinson Disease complications, Parkinson Disease drug therapy, Parkinson Disease epidemiology
- Abstract
Introduction: As the most common cause of autosomal recessive early onset Parkinson's disease (EOPD), parkin type Parkinson's disease (PRKN-PD) may affect female patients in childbearing age. Accordingly, issues related to fertility must be adequately addressed. Here, we landscaped fertile life factors and pregnancy course of a PRKN-PD cohort, including both novel cases directly observed at our center and published ones., Methods: Six patients with confirmed PRKN-PD were examined by a structured interview on reproductive factors and associated modifications of PD disturbances, including one case followed up throughout pregnancy which was described in greater detail. Six studies reporting fertile life factors of nine PRKN-PD patients were reviewed collecting homogeneous data on fertile life and pregnancy course., Results: PRKN-PD female patients experienced motor fluctuations with the menstrual cycle, pregnancy, and puerperium, which suggests a role for sex hormones in PD clinical burden. In some cases, abortion and miscarriages occurred during the organogenesis phase in patients receiving oral antiparkinsonian therapy; however, levodopa/benserazide monotherapy resulted to be the safest choice in pregnancy., Conclusion: Collectively these data disclose the importance of pre-conception counseling in childbearing age PRKN-PD patients and EOPD in general., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
43. Band-Specific Altered Cortical Connectivity in Early Parkinson's Disease and its Clinical Correlates.
- Author
-
Conti M, Guerra A, Pierantozzi M, Bovenzi R, D'Onofrio V, Simonetta C, Cerroni R, Liguori C, Placidi F, Mercuri NB, Di Giuliano F, Schirinzi T, and Stefani A
- Subjects
- Humans, Hypokinesia, Reproducibility of Results, Levodopa therapeutic use, Brain diagnostic imaging, Magnetic Resonance Imaging methods, Parkinson Disease diagnostic imaging
- Abstract
Background: Functional connectivity (FC) has shown promising results in assessing the pathophysiology and identifying early biomarkers of neurodegenerative disorders, such as Parkinson's disease (PD)., Objectives: In this study, we aimed to assess possible resting-state FC abnormalities in early-stage PD patients using high-density electroencephalography (EEG) and to detect their clinical relationship with motor and non-motor PD symptoms., Methods: We enrolled 26 early-stage levodopa naïve PD patients and a group of 20 healthy controls (HC). Data were recorded with 64-channels EEG system and a source-reconstruction method was used to identify brain-region activity. FC was calculated using the weighted phase-lag index in θ, α, and β bands. Additionally, we quantified the unbalancing between β and lower frequencies through a novel index (β-functional ratio [FR]). Statistical analysis was conducted using a network-based statistical approach., Results: PD patients showed hypoconnected networks in θ and α band, involving prefrontal-limbic-temporal and frontoparietal areas, respectively, and a hyperconnected network in the β frequency band, involving sensorimotor-frontal areas. The θ FC network was negatively related to Non-Motor Symptoms Scale scores and α FC to the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale part III gait subscore, whereas β FC and β-FR network were positively linked to the bradykinesia subscore. Changes in θ FC and β-FR showed substantial reliability and high accuracy, precision, sensitivity, and specificity in discriminating PD and HC., Conclusions: Frequency-specific FC changes in PD likely reflect the dysfunction of distinct cortical networks, which occur from the early stage of the disease. These abnormalities are involved in the pathophysiology of specific motor and non-motor PD symptoms, including gait, bradykinesia, mood, and cognition. © 2023 International Parkinson and Movement Disorder Society., (© 2023 International Parkinson and Movement Disorder Society.)
- Published
- 2023
- Full Text
- View/download PDF
44. Exploring the Association Linking Head Position and Sleep Architecture to Motor Impairment in Parkinson's Disease: An Exploratory Study.
- Author
-
Gnarra O, Calvello C, Schirinzi T, Beozzo F, De Masi C, Spanetta M, Fernandes M, Grillo P, Cerroni R, Pierantozzi M, Bassetti CLA, Mercuri NB, Stefani A, and Liguori C
- Abstract
Patients with Parkinson's disease (PD) tend to sleep more frequently in the supine position and less often change head and body position during sleep. Besides sleep quality and continuity, head and body positions are crucial for glymphatic system (GS) activity. This pilot study evaluated sleep architecture and head position during each sleep stage in idiopathic PD patients without cognitive impairment, correlating sleep data to patients' motor and non-motor symptoms (NMS). All patients underwent the multi-night recordings, which were acquired using the Sleep Profiler headband. Sleep parameters, sleep time in each head position, and percentage of slow wave activity (SWA) in sleep, stage 3 of non-REM sleep (N3), and REM sleep in the supine position were extracted. Lastly, correlations with motor impairment and NMS were performed. Twenty PD patients (65.7 ± 8.6 y.o, ten women) were included. Sleep architecture did not change across the different nights of recording and showed the prevalence of sleep performed in the supine position. In addition, SWA and N3 were more frequently in the supine head position, and N3 in the supine decubitus correlated with REM sleep performed in the same position; this latter correlated with the disease duration (correlation coefficient = 0.48, p -value = 0.03) and motor impairment (correlation coefficient = 0.53, p -value = 0.02). These preliminary results demonstrated the importance of monitoring sleep in PD patients, supporting the need for preventive strategies in clinical practice for maintaining the lateral head position during the crucial sleep stages (SWA, N3, REM), essential for permitting the GS function and activity and ensuring brain health.
- Published
- 2023
- Full Text
- View/download PDF
45. Effects of deep brain stimulation of the subthalamic nucleus on patients with Parkinson's disease: a machine-learning voice analysis.
- Author
-
Suppa A, Asci F, Costantini G, Bove F, Piano C, Pistoia F, Cerroni R, Brusa L, Cesarini V, Pietracupa S, Modugno N, Zampogna A, Sucapane P, Pierantozzi M, Tufo T, Pisani A, Peppe A, Stefani A, Calabresi P, Bentivoglio AR, and Saggio G
- Abstract
Introduction: Deep brain stimulation of the subthalamic nucleus (STN-DBS) can exert relevant effects on the voice of patients with Parkinson's disease (PD). In this study, we used artificial intelligence to objectively analyze the voices of PD patients with STN-DBS., Materials and Methods: In a cross-sectional study, we enrolled 108 controls and 101 patients with PD. The cohort of PD was divided into two groups: the first group included 50 patients with STN-DBS, and the second group included 51 patients receiving the best medical treatment. The voices were clinically evaluated using the Unified Parkinson's Disease Rating Scale part-III subitem for voice (UPDRS-III-v). We recorded and then analyzed voices using specific machine-learning algorithms. The likelihood ratio (LR) was also calculated as an objective measure for clinical-instrumental correlations., Results: Clinically, voice impairment was greater in STN-DBS patients than in those who received oral treatment. Using machine learning, we objectively and accurately distinguished between the voices of STN-DBS patients and those under oral treatments. We also found significant clinical-instrumental correlations since the greater the LRs, the higher the UPDRS-III-v scores., Discussion: STN-DBS deteriorates speech in patients with PD, as objectively demonstrated by machine-learning voice analysis., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (Copyright © 2023 Suppa, Asci, Costantini, Bove, Piano, Pistoia, Cerroni, Brusa, Cesarini, Pietracupa, Modugno, Zampogna, Sucapane, Pierantozzi, Tufo, Pisani, Peppe, Stefani, Calabresi, Bentivoglio, Saggio and Lazio DBS Study Group.)
- Published
- 2023
- Full Text
- View/download PDF
46. Enhanced suppression of otoacoustic emissions by contralateral stimulation in Parkinson's disease.
- Author
-
Moleti A, Minniti T, Viziano A, Stefani A, Cerroni R, Garasto E, Pierantozzi M, and Sisto R
- Subjects
- Humans, Dopamine, Otoacoustic Emissions, Spontaneous, Hearing, Acoustic Stimulation, Parkinson Disease diagnosis
- Abstract
Dopamine depletion affects several aspects of hearing function. Previous work [Wu, Yi, Manca, Javaid, Lauer, and Glowatzki, eLife 9, e52419 (2020)] demonstrated the role of dopamine in reducing the firing rates of inner ear cells, which is thought to decrease synaptic excitotoxicity. Thus, a lack of dopamine could indirectly increase acoustic stimulation of medial olivocochlear efferents. To investigate that, here we studied contralateral suppression of distortion product otoacoustic emissions in a population of Parkinsonian patients, compared to an age-matched control group, both audiometrically tested. To rule out activation of the acoustic reflex, middle ear impedance was monitored during testing. The results show significantly stronger contralateral suppression in the patient group., (© 2023 Author(s). All article content, except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).)
- Published
- 2023
- Full Text
- View/download PDF
47. Shaping the course of early-onset Parkinson's disease: insights from a longitudinal cohort.
- Author
-
Bovenzi R, Conti M, Degoli GR, Cerroni R, Simonetta C, Liguori C, Salimei C, Pisani A, Pierantozzi M, Stefani A, Mercuri NB, and Schirinzi T
- Subjects
- Humans, Retrospective Studies, Age of Onset, Levodopa therapeutic use, Brain, Parkinson Disease complications
- Abstract
Introduction: Early -onset Parkinson's disease (EOPD) labels those cases with onset earlier than fifty. Although peculiarities emerged either in clinical or pathological features, EOPD is managed alike typical, late-onset PD. A customized approach would be, instead, better appropriate. Accordingly, a deeper characterization of the clinical course, with an estimation of the disease progression rate, the therapy flow, and the main motor and non-motor complications occurrence, is needed., Methods: A longitudinal cohort of 193 EOPD patients (selected on a single-centre population of 2000 PD cases) was retrospectively analysed, providing descriptive statics on a series of clinical parameters (genetics, phenotype, comorbidities, therapies, motor and non-motor complications, marital and gender issues) and modelling the trajectories from diagnosis to 10 years later of both Hoehn and Yahr (H&Y) stage and levodopa equivalent daily dose (LEDD)., Results: EOPD had a prevalence of 9.7%, including few monogenic cases. It mostly appeared as a motor syndrome, with asymmetric, rigid-akinetic presentation. H&Y linearly progressed with an increment of 0.92 points/10 years; LEDD flow had a non-linear trend, increasing of 526.90 mg/day in 0-5 years, and 166.83 mg/day in 5-10 years. Motor fluctuations started 6.5 ± 3.2 years from onset, affecting up to 80% of the cohort. Neuropsychiatric troubles interested the 50%, sexual complaints the 12%. Gender-specific motor disturbances emerged., Conclusion: We shaped EOPD course, modelling a "brain-first" PD subtype, slowly progressive, with non-linear dopaminergic requirement. Major burden mostly resulted from motor fluctuations, neuropsychiatric complications, sexual and marital complaints, with a considerable gender-effect., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
48. Sex hormones differentially contribute to Parkinson disease in males: A multimodal biomarker study.
- Author
-
Bovenzi R, Sancesario GM, Conti M, Grillo P, Cerroni R, Bissacco J, Forti P, Giannella E, Pieri M, Minosse S, Ferrazzoli V, Pucci N, Laudazi M, Floris R, Garaci F, Pierantozzi M, Stefani A, Mercuri NB, Picchi E, Di Giuliano F, and Schirinzi T
- Subjects
- Humans, Male, alpha-Synuclein cerebrospinal fluid, tau Proteins cerebrospinal fluid, Biomarkers, Amyloid beta-Peptides cerebrospinal fluid, Gonadal Steroid Hormones, Peptide Fragments cerebrospinal fluid, Testosterone, Estradiol, Parkinson Disease complications
- Abstract
Background and Purpose: Parkinson disease (PD) presents relevant sex-related differences in epidemiology, pathophysiology, and clinical features, with males being more vulnerable to the disease. Sex hormones might have a role, as the experimental models suggest; however, human-based evidence is scarce. Here, we integrated multimodal biomarkers to investigate the relationships between circulating sex hormones and clinical-pathological features in male PD patients., Methods: A cohort of 63 male PD patients underwent comprehensive clinical evaluation of motor and nonmotor disturbances; measurement of estradiol, testosterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) blood levels; and cerebrospinal fluid (CSF) assay of total α-synuclein, amyloid-β-42, amyloid-β-40, total tau, and phosphorylated-181 tau levels. A subgroup of 47 PD patients underwent brain volumetry by 3-T magnetic resonance imaging for further correlations. A control group of 56 age-matched individuals was enrolled for comparative analyses., Results: Male PD patients had higher estradiol and testosterone levels than controls. Estradiol had independent inverse associations with Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part 3 score and disease duration; it was also lower in nonfluctuating patients. Testosterone had inverse independent correlations with CSF α-synuclein and right globus pallidus volume. FSH and LH had age-dependent correlations with cognitive impairment and CSF amyloid-β-42/amyloid-β-40 ratio., Conclusions: The study suggested that sex hormones could differentially contribute to clinical-pathological features of PD in male patients. Whereas estradiol might have a protective role in motor impairment, testosterone might be involved in male vulnerability to PD neuropathology. Gonadotropins instead might mediate age-dependent phenomena of amyloidopathy and cognitive decline., (© 2023 European Academy of Neurology.)
- Published
- 2023
- Full Text
- View/download PDF
49. Association between hearing sensitivity and dopamine transporter availability in Parkinson's disease.
- Author
-
Garasto E, Stefani A, Pierantozzi M, Cerroni R, Conti M, Maranesi S, Mercuri NB, Chiaravalloti A, Schillaci O, Viziano A, Moleti A, and Sisto R
- Abstract
In a previous study, we observed: (i) significant hearing function impairment, assessed with pure tone audiometry and distortion product otoacoustic emissions, in patients with Parkinson's disease, compared with a matched control group, and (ii) lateralization of the hearing dysfunction, worse on the side affected by more pronounced Parkinson's disease motor symptoms. This study investigates the association between the basal ganglia dopamine transporter availability and the hearing function in Parkinson's disease patients, focusing also on the lateralization of both dysfunctions, with respect to that of the motor symptoms, and introducing a further distinction between patients with left-sided and right-sided predominant motor symptoms. Patients with right-handed Parkinson's disease with a recent estimation of
123 I-FP-CIT striatal uptake were audiologically tested with pure tone audiometry and distortion product otoacoustic emissions. Thirty-nine patients were included in the study. A statistically significant association was found, in the left-side predominant group only, between the distortion product otoacoustic emission levels and the contralateral dopamine transporter availability, and between the hearing threshold and the dopamine transporter availability difference between the ipsi- and the contralateral sides. The hearing impairment lateralization correlated to the motor symptom asymmetry was found significant only in the left-side predominant patients. The association between hearing function and basal ganglia dopamine transporter availability supports the hypothesis that the peripheral hearing function decline associated with dopamine depletion is involved in Parkinson's disease development, with a significant difference between patients with left- and right-sided predominant motor symptoms. These findings also suggest that peripheral hearing function evaluation and its lateralization could be key elements for subtyping the disease., Competing Interests: The authors report no conflict of interests., (© The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.)- Published
- 2023
- Full Text
- View/download PDF
50. Both Motor and Non-Motor Fluctuations Matter in the Clinical Management of Patients with Parkinson's Disease: An Exploratory Study.
- Author
-
Carpi M, Pierantozzi M, Cofano S, Fernandes M, Cerroni R, De Cillis F, Mercuri NB, Stefani A, and Liguori C
- Abstract
Non-motor symptoms (NMS) characterize the Parkinson's disease (PD) clinical picture, and as well as motor fluctuations, PD patients can also experience NMS fluctuations (NMF). The aim of this observational study was to investigate the presence of NMS and NMF in patients with PD using the recently validated Non-Motor Fluctuation Assessment questionnaire (NoMoFa) and to evaluate their associations with disease characteristics and motor impairment. Patients with PD were consecutively recruited, and NMS, NMF, motor impairment, motor fluctuations, levodopa-equivalent daily dose, and motor performance were evaluated. One-third of the 25 patients included in the study (10 females, 15 males, mean age: 69.9 ± 10.3) showed NMF, and patients with NMF presented a higher number of NMS ( p < 0.01). Static NMS and NoMoFa total score were positively associated with motor performance assessed with the Global Mobility Task ( p < 0.01 and p < 0.001), and the latter was also correlated with motor impairment ( p < 0.05) but not with motor fluctuations. Overall, this study shows evidence that NMF are frequently reported by mild-to-moderate PD patients and associated with an increased number of NMS. The relationship between NoMoFa total score and motor functioning highlights the importance of understanding the clinical role of NMS and NMF in the management of PD patients.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.